SCHEMBL2455815

SCHEMBL2455815

Cc1nnc(Cl)c(-c2cccs2)c1-c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
SMN1; SMN2 Q16637 5/20 0.39
KDM4E B2RXH2 4/20 0.39
NPC1 O15118 2/20 0.39
NFKB1 P19838 2/20 0.39
RAB9A P51151 2/20 0.39
NFKB2 Q00653 2/20 0.39
RELA Q04206 2/20 0.39
LMNA P02545 4/20 0.39
POLB P06746 4/20 0.39
MEN1 O00255 3/20 0.39
KMT2A Q03164 3/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
PKM P14618 1/20 0.39
STAT6 P42226 1/20 0.39
HIF1A Q16665 1/20 0.39
HPGD P15428 2/20 0.38
MAPT P10636 5/20 0.38
F2 P00734 1/20 0.38
HTT P42858 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4610692 0.78 ALDH1A1 (0.37) ALDH1A1SMN1; SMN2KDM4ENPC1NFKB1
SCHEMBL2453901 0.77 NR1I2 (0.41) KDM4ENPC1RAB9AMEN1KMT2A
SCHEMBL2452085 0.75 TYMP (0.46) ALDH1A1SMN1; SMN2KDM4ELMNAPOLB
SCHEMBL896348 0.74 KMT2A (0.40) ALDH1A1KDM4ENPC1RAB9AMEN1
SCHEMBL3618362 0.73 KDM4E (0.36) ALDH1A1SMN1; SMN2KDM4ENPC1NFKB1
SCHEMBL69222 0.73 NPC1 (0.44) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL29369509 0.73 NPC1 (0.44) SMN1; SMN2NPC1RAB9AMEN1KMT2A
SCHEMBL2453925 0.72 MEN1 (0.42) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL896765 0.72 L3MBTL1 (0.48) ALDH1A1SMN1; SMN2KDM4ENPC1RAB9A
SCHEMBL2888290 0.72 NPC1 (0.43) SMN1; SMN2NPC1RAB9AMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1958948-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-10-05 EP disclosed
EP-1958948-B1 PYRIDAZINE COMPOUND AND USE THEREOF SUMITOMO CHEMICAL CO (JP) 2011-10-05 EP disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-8022073-B2 Substituted pyridazine compounds and fungicidal uses thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-09-20 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
US-20090156608-A1 Pyridazine Compound and Use Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-18 US disclosed
EP-1974608-A1 Arylpyridazines as fungicides Bayer CropScience AG (DE) 2008-10-01 EP disclosed
EP-1974608-A1 Arylpyridazines as fungicides Bayer CropScience AG (DE) 2008-10-01 EP disclosed
EP-1958948-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed
EP-1958948-A1 PYRIDAZINE COMPOUND AND USE THEREOF Sumitomo Chemical Company, Limited (JP) 2008-08-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090156608-A1 Pyridazine Compound and Use Thereof PLPBP, PNPO, PDXK ALDH1A1 3397/4885SMN1; SMN2 2463/4885KDM4E 2012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.